Filing Details
- Accession Number:
- 0000899243-16-014987
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-03-02 16:31:45
- Reporting Period:
- 2016-03-01
- Filing Date:
- 2016-03-02
- Accepted Time:
- 2016-03-02 16:31:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 907654 | Arca Biopharma Inc. | ABIO | In Vitro & In Vivo Diagnostic Substances (2835) | 363855489 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1454996 | David Christopher Ozeroff | Arca Biopharma, Inc. 11080 Circlepoint Road, Suite 140 Westminster CO 80020 | S.v.p., General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2016-03-01 | 458 | $3.51 | 19,951 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person for satisfaction of their tax withholding obligation with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Equity Incentive Plan (the "Plan").
- Includes (i) remaining 3,571 previously reported shares issued as RSUs under the Plan that vest on 9/17/16, (ii) remaining 2,443 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (iii) 3,435 previously reported shares issued as RSUs under the Plan that vest in three equal annual installments beginning April 2, 2016, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 10,502 previously reported shares of common stock held directly.
- The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $3.47 to $3.53. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
